(35 days)
Not Found
No
The document explicitly states that the analysis module provides ECG measurements but "does not make any interpretation of the intervals provided based on factors such as heart rate, QRS duration, etc.", which is a common application of AI/ML in ECG analysis. There is no mention of AI, ML, or related terms like deep learning or neural networks.
No
The device is used to acquire, record, and transmit electrocardiographic signals for review, not to directly treat or provide therapy to a patient.
Yes
The device acquires, records, and processes an electrocardiographic signal for review by a physician or other medical receiving centers, which is a diagnostic purpose. While it states it does not make interpretations, it provides the data for clinical interpretation, fitting the definition of a diagnostic device.
No
The device description explicitly lists multiple hardware components, including the "QT ECG Recorder" and the "QT ECG Electrode Strip," in addition to the software components.
Based on the provided information, the QT ECG System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information about a person's health. This testing is done outside of the body (in vitro).
- QT ECG System Function: The QT ECG System acquires and records an electrocardiographic signal directly from the patient's body. This is a measurement of electrical activity within the body, not an analysis of a specimen taken from the body.
- Intended Use: The intended use clearly states that the system is for acquiring, recording, and processing an electrocardiographic signal for transmission and review. It does not mention the analysis of biological specimens.
Therefore, the QT ECG System falls under the category of a medical device that performs a physiological measurement, but it is not an IVD.
N/A
Intended Use / Indications for Use
The QT ECG System is intended to acquire, record and process an electrocardiographic signal so that it can be transmitted digitally via Bluetooth technology to a cell-phone or mobile device, then to a remote location. The QT ECG System is indicated for use on infants, children and adults. It is designed to be operated by adults in the home, or by healthcare workers in non-acute care clinical facilities (such as nursing homes, skilled nursing facilities), and in professional healthcare facilities (such as clinics, hospitals, and ambulances) to record and transmit a 12- lead ECG and rhythm strip in near real-time to enable review at a physician's office, hospital or other medical receiving centers.
Product codes (comma separated list FDA assigned to the subject device)
DXH
Device Description
The QT ECG system is a non-defibrillator-proof, hand-held, cordless 12-lead electrocardiograph (ECG) system with Bluetooth connectivity. The QT ECG system consists of 5 major components:
- The QT ECG Recorder-Compact device that records 12-lead, resting electrocardiograms, then transmits the recorded data to a mobile device (smartphone, tablet, etc.) paired via Bluetooth. A Bluetooth-enabled mobile device (not included) is needed to operate the QT ECG Recorder, and to send the recorded rhythm strip to a cardiologist or licensed physician for review.
- The QT ECG Electrode Strip-Disposable, patented electrodes that are prepositioned on a self-adhesive strip.
- The QT ECG App - Software that lets the user uses their mobile device to operate the QT ECG recorder, then send the recorded data via cloud to a certified medical professional for review.
- Analysis The analysis module provides ECG measurement from the collected data. It does not make any interpretation of the intervals provided based on factors such as heart rate, QRS duration, etc.
- Web Service - The web service provides an interface for communication. The recorded ECG data is saved temporarily on the mobile device until it is transferred via the Internet to the cloud server. The QT ECG System does not have monitoring capabilities and does not have diagnostic alarm function. The QT ECG System is indicated for use on infants, children and adults. It is designed to be operated by adults in the home, or by healthcare workers in non-acute care clinical facilities (such as nursing homes, skilled nursing facilities), and in professional healthcare facilities (such as clinics, hospitals, and ambulances) to record and transmit a 12- lead ECG and rhythm strip in near real-time to enable review at a physician's office, hospital or other medical receiving centers.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
infants, children and adults
Intended User / Care Setting
operated by adults in the home, or by healthcare workers in non-acute care clinical facilities (such as nursing homes, skilled nursing facilities), and in professional healthcare facilities (such as clinics, hospitals, and ambulances)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical Testing: An validation activity was conducted on the subject device according to IEC 60601-1-12 (EMS, Emergency Medical Services), QT ECG.
Key results: Pass. The risk is controlled. The document: Risk Management Plan, Risk Control Report, Risk Management Summary, Report of IEC 60601-1-12.
Software Validation and Cybersecurity Evaluation: Conduct the software system test.
Key results: Pass. The risk is controlled. The document: Risk_Management_Plan, Risk_Control_Report, Risk_Management_Summary, Software Test reports: Unit Test, Integration Test, System Test.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.2920 Telephone electrocardiograph transmitter and receiver.
(a)
Identification. A telephone electrocardiograph transmitter and receiver is a device used to condition an electrocardiograph signal so that it can be transmitted via a telephone line to another location. This device also includes a receiver that reconditions the received signal into its original format so that it can be displayed. The device includes devices used to transmit and receive pacemaker signals.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
QT Medical Inc. Jui-Hung Hung Senior Quality Assurance Engineer 1370 Valley Vista Drive, Suite 266 Diamond Bar, California 91765
Re: K233521
Trade/Device Name: QT ECG (QTERD100) Regulation Number: 21 CFR 870.2920 Regulation Name: Telephone Electrocardiograph Transmitter And Receiver Regulatory Class: Class II Product Code: DXH, DRX Dated: November 1, 2023 Received: November 1, 2023
Dear Jui-Hung Hung:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
1
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Robert T. Kazmierski -S
for
Jennifer Shih Kozen Assistant Director Division of Cardiac Electrophysiology, Diagnostics, and Monitoring Devices Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
2
Indications for Use
Submission Number (if known)
Device Name
QT ECG (QTERD100)
Indications for Use (Describe)
The QT ECG System is intended to acquire, record and process an electrocardiographic signal so that it can be transmitted digitally via Bluetooth technology to a cell-phone or mobile device, then to a remote location. The QT ECG System is indicated for use on infants, children and adults. It is designed to be operated by adults in the home, or by healthcare workers in non-acute care clinical facilities (such as nursing homes, skilled nursing facilities), and in professional healthcare facilities (such as clinics, hospitals, and ambulances) to record and transmit a 12- lead ECG and rhythm strip in near real-time to enable review at a physician's office, hospital or other medical receiving centers.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
12. Type of Submission: Special 510(k), 510(k) number: K233521
12.1. Date of Summary:10/31/2023
12.2. Submitter: QT MEDICAL. Inc.
- Address: 1370 Valley Vista Dr., Suite 266, Diamond Bar, CA 12.2.1. 91765, USA
- 12.2.2. Phone:1-(909) 323-0007
- 12.2.3. Fax:1-(310) 755-3108
- 12.2.4. Representative: Ruey-Kang Chang, CEO
(rk.chang@gtmedical.com)
12.3. Identification of the Device
- 12.3.1. Proprietary/ Trade name: QT ECG
- 12.3.2. Classification Product Code: DXH
- 12.3.3. Regulation Number: 870.2920
- 12.3.4. Regulation Description:Telephone electrocardiograph transmitter and receiver
- 12.3.5. Review Panel: Cardiovascular
- 12.3.6. Device Class: II
12.4. Identification of the predicate Device
- 12.4.1. Original Device Name: QT ECG
- 12.4.2. Manufacturer: QT Medical, Inc.
- Classification Product Code: DXH 12.4.3.
- Regulation number: 870.2920 12.4.4.
- 12.4.5. Device Class: II
- 510(k) Number: K220795 12.4.6.
12.5. Indication for Use of the Device
Indication for Use: 12.5.1.
The QT ECG System is intended to acquire, record and process an electrocardiographic signal so that it can be transmitted digitally via Bluetooth technology to a cell-phone or mobile device, then to a remote location. The QT ECG System is indicated for use on infants, children and adults. It is designed to be operated by adults in the home, or by healthcare workers in non-acute care clinical facilities (such as nursing homes, skilled nursing facilities), and in professional healthcare facilities (such as clinics, hospitals, and ambulances) to record and transmit a 12- lead ECG and rhythm strip in near real-time to enable review at a physician's office, hospital or other medical receiving centers. 12.5.2. Intended Use:
The QT ECG System is intended to condition an electrocardiographic signal so that it can be transmitted digitally via Bluetooth technology and cell-phone or communication device to a remote location. The QT ECG System is designed to be used by an adult or a healthcare worker to transmit a 12-lead ECG and rhythm strip in near real-time to enable review at a physician's office, hospital or other medical receiving center.
Device Description 12.6.
The QT ECG system is a non-defibrillator-proof, hand-held, cordless 12-lead
4
electrocardiograph (ECG) system with Bluetooth connectivity. The QT ECG system consists of 5 maior components:
- · The QT ECG Recorder-Compact device that records 12-lead, resting electrocardiograms, then transmits the recorded data to a mobile device (smartphone, tablet, etc.) paired via Bluetooth. A Bluetooth-enabled mobile device (not included) is needed to operate the QT ECG Recorder, and to send the recorded rhythm strip to a cardiologist or licensed physician for review.
- . The QT ECG Electrode Strip-Disposable, patented electrodes that are prepositioned on a self-adhesive strip.
- . The QT ECG App - Software that lets the user uses their mobile device to operate the QT ECG recorder, then send the recorded data via cloud to a certified medical professional for review.
- Analysis The analysis module provides ECG measurement from the . collected data. It does not make any interpretation of the intervals provided based on factors such as heart rate, QRS duration, etc.
Web Service - The web service provides an interface for communication. . The recorded ECG data is saved temporarily on the mobile device until it is transferred via the Internet to the cloud server. The QT ECG System does not have monitoring capabilities and does not have diagnostic alarm function. The QT ECG System is indicated for use on infants, children and adults. It is designed to be operated by adults in the home, or by healthcare workers in non-acute care clinical facilities (such as nursing homes, skilled nursing facilities), and in professional healthcare facilities (such as clinics, hospitals, and ambulances) to record and transmit a 12- lead ECG and rhythm strip in near real-time to enable review at a physician's office, hospital or other medical receiving centers.
12.7. Non-clinical Testing
An validation activity was conducted on the subject device according to IEC 60601-1-12 (EMS, Emergency Medical Services), QT ECG.
5
The list of claimed standards and regulations for compliance:
| Testing Item | FDA Recognition No. | Standards and Regulations Applied |
|---|---|---|
| - | Good Laboratory Practice for Nonclinical Laboratory Studies. Title 21 of | |
| the U.S. Code of Federal Regulations, | ||
| Part 58 United States Food and Drug Administration. | ||
| Biocompatibility | - | Use of International Standard ISO 10993-1, "Biological evaluation of |
| medical devices - Part 1: Evaluation and testing within a risk | ||
| management process". | ||
| 2-222 | ISO 10993-2:2006, Biological evaluation of medical devices -- Part 2: | |
| Animal welfare requirements. | ||
| 2-245 | ISO 10993-5:2009, Biological evaluation of medical devices -- Part 5: | |
| Tests for in vitro cytotoxicity. | ||
| 2-174 | ISO 10993-10:2010, Biological evaluation of medical devices -- Part 10: | |
| Tests for irritation and skin sensitization. | ||
| 2-191 | ISO 10993-12:2012, Biological evaluation of medical devices -- Part 12: | |
| Sample preparation and reference materials. | ||
| 2-191 | ANSI/AAMI/ISO 10993-12:2012, Biological Evaluation Of Medical | |
| Devices - Part 12: Sample Preparation | ||
| And Reference Materials. | ||
| - | Guidance for the Content of Premarket Submissions for Software | |
| Contained in Medical Devices: 2005. | ||
| Software Validation and | ||
| Cybersecurity Evaluation | - | Guidance on Off-The-Shelf Software Use in Medical Devices: 2019. |
| - | Guidance for content of Premarket Submissions for Management of | |
| Cybersecurity in Medical Devices: 2014. | ||
| Electromagnetic | ||
| Compatibility | ||
| and Electrical | ||
| Safety | 13-79 | IEC 62304:2006+AMD1:2015, Medical device software - Software life |
| cycle processes. | ||
| 5-125 | ISO 14971:2019, Medical devices - Application of risk management to | |
| medical devices. | ||
| 3-105 | ANSI/AAMI/IEC 60601-2-25:2011/(R)2016, Medical electrical equipment - | |
| Part 2-25: Particular requirements | ||
| for the basic safety and essential performance of electrocardiographs. | ||
| - | Guidance on Information to Support a Claim of Electromagnetic | |
| Compatibility (EMC) of Electrically-Powered Medical Devices: 2016. | ||
| 19-4 | ANSI/AAMI ES60601-1: 2005 / A2:2010, Medical electrical equipment - | |
| Part 1: General requirements for basic safety and essential performance. | ||
| 19-8 | IEC 60601-1-2:2014, Medical electrical equipment - Part 1-2: General | |
| requirements for basic safety and essential performance - Collateral | ||
| standard: Electromagnetic compatibility. | ||
| 19-14 | IEC 60601-1-11:2015, Medical electrical equipment - Part 1-11: General | |
| requirements for basic safety and | ||
| essential performance - Collateral standard: Requirements for medical | ||
| electrical equipment and medical | ||
| electrical systems used in the home healthcare environment. | ||
| 3-105 | IEC 60601-2-25:2011, Medical electrical equipment - Part 2-25: Particular | |
| requirements for the basic safety and essential performance of | ||
| electrocardiographs. | ||
| 19-13 | IEC 62133:2012, Secondary cells and batteries containing alkaline or | |
| other non-acid electrolytes - Safety | ||
| requirements for portable sealed secondary cells, and for batteries made | ||
| from them, for use in portable | ||
| applications. | ||
| Performance | 3-52 | ANSI/AAMI EC12:2000/(R)2015, Disposable ECG electrodes. |
| Performance | 19-13 | IEC 62133:2012, Secondary cells and batteries containing alkaline or |
| other non-acid electrolytes - Safety requirements for portable sealed | ||
| secondary cells, and for batteries made from them, for use in portable | ||
| applications. | ||
| Performance | 19-39 | IEC 60601-1-12:2014, AMD1:2020 (excepted for clause 9) |
| Human Factor | - | Guidance on Applying Human Factors and Usability Engineering to |
| Medical Devices: 2016. |
6
7
12.8. Description of the change(s) and unchange(s)
The QT ECG submitted in this 510(k) file is compared with the cleared device, former QT ECG (K220795). Differences between the devices are cited as below, and other technological specifications are all the same as that of K220795. The new use environment is EMS, so the risk management and verification activities in our design and development control process are all completed.
All Differences between Subject Device and Original Device
| Device Change | Risk | Subject Device(K233521) | Original Device (K220795) | Verification/ Validation
Method(s) | Acceptance Criteria | Summary of Results | |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Indications for Use | The recorder may
be used in EMS
(Emergency
Medical Services),
it may malfunction. | The QT ECG System is intended to
acquire, record and process an
electrocardiographic signal so that it
can be transmitted digitally via
Bluetooth technology to a cell-phone or
mobile device, then to a remote
location. The QT ECG System is
indicated for use on infants, children
and adults. It is designed to be
operated by adults in the home, or by
healthcare workers in non-acute care
clinical facilities (such as nursing
homes, skilled nursing facilities), and in
professional healthcare facilities (such | The QT ECG System is intended
to acquire, record and process
an electrocardiographic signal so
that it can be transmitted digitally
via Bluetooth technology to a
cell-phone or mobile device,
then to a remote location. The
QT ECG System is indicated for
use on infants, children and
adults. It is designed to be
operated by adults in the home,
or by healthcare workers in
non-acute care clinical facilities
(such as nursing homes, skilled
nursing facilities), to record and
transmit a 12-lead ECG and
rhythm strip in near real-time to | Undergo the test according
to IEC 60601-1-12. | Pass the test according to
IEC 60601-1-12. | Pass.
The risk is controlled.
The document:
Risk Management Plan
Risk Control Report
Risk Management Summary
Report of IEC 60601-1-12 | |
| | | | | | | | |
| Storage and
transport
temperature | | as clinics, hospitals, and ambulances)
to record and transmit a 12- lead ECG
and rhythm strip in near real-time to
enable review at a physician's office,
hospital or other medical receiving
centers. | enable review at a physician's
office, hospital or other medical
receiving centers. | | | | |
| Storage and
transport
temperature | | -40°C ~ 70°C; -40°F158°F | -25°C70°C; -13°F158°F | | | | |158°F | -25°C
| Operating
Temperature | | -40°C ~ 70°C; -40°F70°C; -13°F158°F | | | | |
| Storage and
Transport
Atmospheric
Pressure | | 620 hPa ~ 1060 hPa | 700 hPa ~ 1060 hPa | | | | |
| Operating
Atmospheric
Pressure | | 620 hPa ~ 1060 hPa | 700 hPa ~ 1060 hPa | | | | |
| Ingress Protection
Rating | | IP33 | IP22 | | | | |
| Package | - | Package (Remove Small White Box):
Small Blue Box, Industrial Package. | Package:
Small White Box, Small Blue
box, Industrial Package. | It's no need to conduct
Verification/ Validation
Method(s) because the
small white box is no longer
in use. | N/A | N/A | |
| Quick guide | | Simplify the quick
guide for reducing
risks and there is
no other risk. | Update the quick guide to
02-C1-07-V3-R0-01 Quick Guide) | Quick guide (02-C1-07-V2-R4) | It's no need to conduct
Verification/ Validation
Method(s) because the
quick guide is for reducing
risks and there is no other
risk. | N/A | N/A |
8
9
| Mobile device | New mobile
system version is
not supported. | On Phone:
iPhone 13 Pro Max (iOS 15)
iPhone 13 Pro (iOS 15)
iPhone 13 (iOS 15)
iPhone 13 mini (iOS 15)
iPhone 12 Pro Max (iOS 15)
iPhone 12 Pro (iOS 15)
iPhone 12 (iOS 15)
iPhone 12 mini (iOS 15)
iPhone 11 Pro Max (iOS 15)
iPhone 11 Pro (iOS 15)
iPhone 11 (iOS 15)
iPhone XS Max (iOS 15)
iPhone XS (iOS 15)
iPhone XR (iOS 15)
iPhone X (iOS 15)
iPhone 8/ 8 Plus (iOS 15)
iPhone 7/ 7 Plus (iOS 15)
iPhone 6S/ 6S Plus (iOS 15)
iPhone SE 2 (iOS 15)
Samsung Galaxy S10 (Android 11)
Samsung Galaxy S9 (Android 10)
Samsung Galaxy S9+ (Android 10)
Samsung Galaxy S8 (Android 9)
Samsung Galaxy S8+ (Android 9)
Samsung Galaxy A21s (Android
11)
Samsung Galaxy A20 (Android 11)
LG G7 (Android 9)
LG G6 (Android 9)
Google Pixel 2 (Android 11)
Google Pixel 2 XL (Android 11)
Google Pixel (Android 10)
Google Pixel XL (Android 10)
On Tablet:
iPad Pro 11 inch/2020 (iOS 15)
iPad Pro 11 inch/2018 (iOS 15)
iPad 9th/2021 (iOS 15)
iPad 8th/2020 (iOS 15)
iPad 7th/2019 (iOS 15)
iPad 6th/2018 (iOS 15)
iPad 5th/2017 (iOS 15)
iPad mini 6 (iOS 15)
iPad mini 5 (iOS 15)
iPad mini 4 (iOS 15)
iPad Air 2 (iOS 15) | on Phone:
iPhone 11 Pro Max (iOS 13.5)
iPhone 11 Pro (iOS 13.5)
iPhone 11 (iOS 13.5)
iPhone XS Max (iOS 13.5)
iPhone XS (iOS 13.5)
iPhone XR (iOS 13.5)
iPhone X (iOS 13.5)
iPhone 8/ 8 Plus (iOS 13.5)
iPhone 7/ 7 Plus (iOS 13.5)
iPhone 6S/ 6S Plus (iOS 13.5)
iPhone 6/ 6 Plus (iOS 12.4.7)
iPhone SE (iOS 13.5)
iPhone SE 2 (iOS 13.5)
iPod touch (6th) (iOS 12.4.7)
Samsung Galaxy S9 (Android 9)
Samsung Galaxy S9+ (Android
9)
Samsung Galaxy S8 (Android 9)
Samsung Galaxy S8+ (Android
9)
LG G7 (Android 8.0.0)
LG G6 (Android 8.0.0)
LG G5 (Android 8.0.0)
Google Pixel 2 (Android 10)
Google Pixel 2 XL (Android 10)
Google Pixel (Android 10)
Google Pixel XL (Android 10)
on Tablet:
iPad 7th/2019 (iOS 13.5)
iPad 6th/2018 (iOS 13.5)
iPad 5th/2017 (iOS 13.5)
iPad mini 5 (iOS 13.5)
iPad mini 4 (iOS 13.5)
iPad mini 3 (iOS 12.4.7) | Conduct the software
system test. | Pass criteria according to
test reports:
Unit Test
Integration Test
System Test | Pass. The risk is controlled
The document:
Risk_Management_Plan
Risk_Control_Report
Risk_Management_Summary
Software Test reports:
Unit Test
Integration Test
System Test |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | | | |
| iPad Air 4 (iOS 15)
Samsung Tab S4 (Android 10)
Samsung Tab S3 (Android 10)
Samsung Tab A 10.1" 2019
(Android 11)
Samsung Tab A7 (Android 11)
Lenovo Tab 4 8 Plus (Android
8.1.0)
Asus Zenpad 3s 10 (Android 7.0)
Asus Zenpad 3 8.0 (Android 7.0) | | | | | | |
10
12.9. Similarity and Difference
The QT ECG has been compared with the former "QT ECG" (K220795). The subject device has similar indications for use, same technology/mechanism of action, and similar safety and performance as the original device. The usage ny Medical Services (EMS) in the objective device, which operates during emergency situations in compliance with IEC 60601-1-12.
Although there are some different specifications between two devices, the software validation, performance test and usability test have been completed to demonstrate that the differences between these parameters would not impact the subject device. The subject device has also undergone all safety and performance tests, and the results complied with the test requests.
Therefore, the difference between the subject device did not raise any problem of substantial equivalence. The subject device is substantially equivalent to the original device in intended use, safety and performance claims.
12.10. Conclusion
After analyzing all testing data and comparing with the original device, it can be concluded that the QT ECG is substantially equivalent to the original device.